Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights

Get insights on Bafna Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Bafna Pharmaceuticals Ltd Share Price Chart

Bafna Pharmaceuticals Ltd Fundamentals

Traded Volume: 23

Market Cap(Cr): 437

Avg Traded Price 60.21

1 Year return 129.65%

Upper Circuit 184.9

Lower Circuit 184.9

P/E TTM 50.00

P/B Ratio 4.00

Traded Value(Cr) 0.04

EPS TTM 3.708

Book value 3.708

Dividend 0.00%

Bafna Pharmaceuticals Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Bafna Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Bafna Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +11.20%

1M +18.48%

3M +104.41%

1Y +129.65%

YTD +127.95%

Bafna Pharmaceuticals Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Bafna Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 28303.00

Day Before Yesterday 12575.00

1W Avg 12867.40

1M Avg 5257.00

3M Avg 21278.36

Bafna Pharmaceuticals Ltd Technical Details

Bafna Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 180

Support 2 172

Support 3 161

Pivot Point : 191

Resistance 1 200

Resistance 2 210

Resistance 3 219

Bafna Pharmaceuticals Ltd Corporate Actions

Bafna Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Bafna Pharmaceuticals Ltd’s capital allocation strategies.

All

Ex-Date 19-Sep-2013 Type D Description 0.60/share@6.00% Record Date 13-Nov-2025 Ratio 6.00

Dividends

Announcement Date 19-Sep-2013 Ex Dividend Date 19-Sep-2013 Dividend(%) 6

Bonus

No Bonus has been declared by BAFNAPH

Splits

No Split has been declared by BAFNAPH

Others

Rights No Rights has been declared by BAFNAPH

Bafna Pharmaceuticals Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Bafna Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Bafna Pharmaceuticals Ltd's relative performance and valuation against major competitors.

Stock Name Kerala Ayurveda Ltd ₹390.00 (-1.49%) M. Cap (Cr) 4.70 1 Yr Return (%) +49.11% P/E (TTM) -36.04 PB Ratio 11.53

Stock Name Amanta Healthcare Ltd ₹118.67 (-3.33%) M. Cap (Cr) 4.61 1 Yr Return (%) NaN% P/E (TTM) PB Ratio 4.33

Stock Name Influx Healthtech Ltd ₹198.05 (+4.98%) M. Cap (Cr) 4.58 1 Yr Return (%) NaN% P/E (TTM) 34.30 PB Ratio 11.14

Stock Name Bafna Pharmaceuticals Ltd ₹184.87 (-2.00%) M. Cap (Cr) 4.37 1 Yr Return (%) +129.65% P/E (TTM) 49.85 PB Ratio 5.16

Stock Name Medico Remedies Ltd ₹53.19 (+0.47%) M. Cap (Cr) 4.41 1 Yr Return (%) -5.42% P/E (TTM) 42.72 PB Ratio 7.07

Stock Name Valiant Laboratories Ltd ₹79.67 (-0.88%) M. Cap (Cr) 4.33 1 Yr Return (%) -22.71% P/E (TTM) 85.35 PB Ratio 1.37

Stock Name Everest Organics Ltd ₹408.00 (+2.32%) M. Cap (Cr) 3.96 1 Yr Return (%) +255.25% P/E (TTM) 63.92 PB Ratio 9.39

Bafna Pharmaceuticals Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Bafna Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 22.14 Mar 2024 9.48 Mar 2023 4.95 Mar 2022 8.03 Mar 2021 -13.61

PARTICULARS Investing Activities Mar 2025 -21.16 Mar 2024 -15.05 Mar 2023 -7.49 Mar 2022 -5.44 Mar 2021 -5.35

PARTICULARS Financing Activities Mar 2025 1.06 Mar 2024 -0.85 Mar 2023 10.18 Mar 2022 -4.22 Mar 2021 12.28

PARTICULARS Net Cash Flow Mar 2025 2.04 Mar 2024 -6.41 Mar 2023 7.64 Mar 2022 -1.63 Mar 2021 -6.68

Bafna Pharmaceuticals Ltd Shareholding Pattern

This shows the ownership breakdown of Bafna Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 75.0%

Public 15.66%

Other Institutions 0.0%

FII 9.34%

Mutual Funds null%

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The company`s first product was registered in Srilanka in 1995 and the company made its first export during the same year. Presently around 57 products of the company are registered in Srilanka. During the year 2000 Bafna registered 3 of its products in Lao and in the year 2006, 4 products were registered in Ukraine. During 2007, Bafna registered 1 product in Ghana. The products registered by the company cover all the therapeutic segments. In the year 2003, the Government of India granted the Export House status to the company. The company received the Best Supplier award from the Srilankan Government during 2005. After establishing itself in the non -regulated market, the company decided to enter into a more lucrative and regulated market of Europe. Towards this objective, the company started construction of a new state of art facility at Grantlayon village, near Red hills, Chennai for the manufacture of Non Betalactum products in solid oral dosage form during 2005. This unit is a 100% EOU unit. The factory was completed and inaugurated on October 2, 2006. This new plant has been set up with guidelines as laid down in European GMP. The machineries installed in the new facility of the company are Programmable Logic Controller and all the contact parts are made of stainless steel. This leads to consistent quality of products produced with no contamination. The Auto Coater machinery used in the unit is imported from Korea and Camera system for detection of unfilled product is imported from USA. The company has entered into an agreement with an UK based company Somex Pharma for sale of cholesterol lowering agent products to be manufactured by Bafna at this unit. A full-scale commercial production would be commenced in the new unit once approval of MHRA is received. Presently company is validating the equipments and process at this unit and taking validation batches for trail run. The Company launched "Raricap? to domestic market in FY 12. It again launched three more brands namely BSF (Dietary Supplement), Molev (Antiasthamics) and Lopih (Lowering pregnancy induced hypertension) segments for women wellness. In 2022, it expanded operations and set up manufacturing facilities in Chennai, India, with UK-MHRA & TGA- Australia accreditations, with round the year exports to prestigious Regulated Markets and Emerging markets.

Non-Exec. & Independent Dir.

Babulal Kamlesh Kumar

Registered office Bafna Towers New No 68, Old No 299 Thambu Chetty St, Chennai, Tamil Nadu, 600001

FAX :91-44-25267517/25270992/4267755

Background

Incorporation Year 1995

Face Value ₹10.00

Market Lot 1

Bafna Pharmaceuticals Ltd Latest News

VIEW MORE NEWS

FAQs on Bafna Pharmaceuticals Ltd